| Title | Equivalent outcomes with primary and retransplantation in African-American deceased-donor renal allograft recipients. | | Author(s) | Gruber SA, Brown KL, El-Amm JM, Singh A, Mehta K, Morawski K, Cincotta E, Nehlsen-Cannarella S, Losanoff JE, West MS, Doshi MD | | Institution | Section of Transplant Surgery, Department of Surgery, Wayne State University School of Medicine, Detroit, MI, USA. sgruber@dmc.org | | Source | Surgery 2009 Oct; 146(4):646-52; discussion 652-3. | | MeSH | Adult
African Americans
Female
Graft Survival
HLA-DR Antigens
Histocompatibility Testing
Humans
Kidney Transplantation
Male
Middle Aged
Reoperation
Retrospective Studies
Tissue Donors
Transplantation, Homologous
| | Abstract | BACKGROUND: Graft survival following renal retransplantation has been inferior to that following primary allografting, particularly in African Americans (AAs) receiving deceased-donor (DD) kidneys.
METHODS: Among 166 AA DD renal allograft recipients transplanted from July 2001 through July 2007, we compared the outcomes of 26 (16%) receiving a second graft with those of 140 primary cases. All patients received either thymoglobulin (ATG) or an IL-2 receptor antagonist for induction, and were maintained on either tacrolimus or sirolimus + mycophenolate mofetil +/- prednisone.
RESULTS: When compared with primary transplants, regrafts received kidneys from older donors, were younger, more sensitized, more likely to receive ATG and to be maintained on prednisone, received more doses of ATG, and were less likely diabetic. There was no difference between primary and retransplant groups in overall patient or graft survival; incidence of acute rejection, CMV infection, BK nephropathy, or new-onset diabetes mellitus; and serum creatinine at 1 year.
CONCLUSION: AA renal allograft recipients can undergo a second DD transplant with intermediate-term outcomes comparable to that of a primary graft, despite the presence of multiple immunologic and non-immunologic high-risk factors, by extending the course of ATG induction and continuing prednisone therapy in the vast majority of cases. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19789023 |
|
